archived version — not current

This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-23. It does not reflect the current, live profile. View the current profile.

Glucagon

Snapshot captured 2026-09-23 — Published content materially edited

Overview

Glucagon is an endogenous peptide hormone central to glucose regulation. The hormone, glucagon-containing medicines, and drugs that target glucagon or GLP-1 pathways answer different biological and clinical questions.

Evidence quality

WPF’s broad Glucagon atlas includes glucose-homeostasis research, stimulation-test studies, and many records about related incretin drugs. The screening inventory is not a curated list of direct evidence about every use of glucagon, and adjacent GLP-1 literature should not be attributed to glucagon itself.

Safety concerns

This Directory entry has no published source-linked citations or jurisdiction-specific regulatory records. A mechanism statement must not be converted into an efficacy claim for a particular product, formulation, route, or clinical scenario.

Citations as of this version

Regulatory status as of this version

United States — FDA: approved — GlucaGen (glucagon), specifically -- not glucagon as a class: indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes, and separately indicated as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adult patients only.
European Union — EMA: approved — Baqsimi (glucagon nasal powder) is centrally authorized for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Content hash: 48bf175e73542e46ae86d3c657b70a1b3324de211ec3c004d3dc5897d6fa0830

All archived versions